Drug Safety Update
August 2015: Sofosbuvir and sofosbuvir combination regimens: risk of severe bradycardia and heart block when taken with amiodarone.
January 2017: Direct acting antiviral interferon-free regimens to treat chronic hepatitis C - risk of hepatitis B reactivation
January 2017: Direct acting antiviral interferon-free regimens to treat chronic hepatitis C - risk of interaction with vitamin K antagonists and changes in INR
October 2018: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
December 2018: Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes
